Carrick Therapeutics, Ltd.
100 Victoria Embankment
About Carrick Therapeutics, Ltd.Carrick Therapeutics is pioneering a portfolio of unique first-in-class cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumour. Carrick means 'rock' in Irish, the name having been chosen to emphasise the strong foundation of like-minded scientists, collaborators and investors, and the vision to build a world-class company. Carrick has an ambitious patient-focussed vision to serve cancer patients around the world by the introduction of ground-breaking cancer therapies that will transform the way cancer is treated.
CEO: Dr. Elaine Sullivan
14 articles with Carrick Therapeutics, Ltd.
Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at the 2021 San Antonio Breast Cancer Symposium
Carrick Therapeutics today announces two presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held from December 7-10, 2021.
Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, presented encouraging initial clinical data on samuraciclib, an oral and first-in-class inhibitor of CDK7, at the 2021 European Society of Medical Oncology Congress.
Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021
Carrick Therapeutics today announces two presentations at the European Society for Medical Oncology (ESMO) Congress, to be held from September 16-21, 2021.
Two experimental cancer drugs, one for ovarian cancer and one for a form of breast cancer, received Fast Track designation from the U.S. FDA, which will speed up the regulatory process for these medications.
Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2ꟷ Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer
Carrick Therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib for the treatment of locally advanced or metastatic triple negative breast cancer.
Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer
Carrick Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2- advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer.
Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer
Carrick Therapeutics today announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer.
CARRICK THERAPEUTICS ANNOUNCES PLAN TO ESTABLISH US OPERATIONS AND APPOINTMENT OF TIM PEARSON AS CEO
Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has today announced that it plans to establish business operations in Boston, Massachusetts, and the transition of leadership from Elaine Sullivan, based in Dublin, to Tim Pearson, based in Boston, Massachusetts.
Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman
Exclusive worldwide licence deal adding to Carrick's rapid pipeline expansion
BlackThorn Therapeutics today announced the appointment of a key strategic executive to the company’s board of directors, George S. Golumbeski, Ph.D.
Carrick Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of its Oral CDK7 Inhibitor: CT7001
Efficacy studies are planned to start in 2018.
New Startup Carrick Therapeutics Launches With $95 Million and Taps Former AstraZeneca PLC-Eli Lilly Exec as CEO